Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 8
Submit an article Journal homepage
203
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review

Julie FuDivision for Hematology/Oncology, Tufts Medical Center, Boston, MA, USA; ;Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA, USA; ;Tufts University School of Medicine, Boston, MA, USA; ;Tufts Medical Center Cancer Center of Stoneham, Stoneham, MA, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9468-4949
ORCID Icon,
Jenica UpshawTufts University School of Medicine, Boston, MA, USA; ;CardioVascular Center, Tufts Medical Center, Boston, MA, USA;
,
Joshua CohenTufts University School of Medicine, Boston, MA, USA; ;Center for the Evaluation of Value and Risk in Health (ICRHPS), Tufts Medical Center, Boston, MA, USA;
,
Angie Mae RoddayCenter for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA, USA; ;Tufts University School of Medicine, Boston, MA, USA;
,
Tully SaundersCenter for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA, USA;
,
Michael KellyTufts University School of Medicine, Boston, MA, USA; ;Division of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA
,
Andrew M. EvensDivision for Hematology/Oncology, Tufts Medical Center, Boston, MA, USA; ;Tufts University School of Medicine, Boston, MA, USA;
&
Susan K. ParsonsDivision for Hematology/Oncology, Tufts Medical Center, Boston, MA, USA; ;Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA, USA; ;Tufts University School of Medicine, Boston, MA, USA;
show all
Pages 1976-1980 | Received 27 Apr 2017, Accepted 12 Nov 2017, Published online: 07 Dec 2017

References

  • Surveillance Research Program NCI. Cancer stat facts: Hodgkin lymphoma [Internet]; 2016. Surveillance Epidemiology & End Results Program (SEER) data base. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
  • Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35:1786–1794.
  • Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372:1598–1607.
  • Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154:23–31.
  • Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412–418.
  • Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49:1486–1493.
  • Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323–329.
  • Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol. 2017;28:2179–2184.
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6:e1000097.
  • Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.
  • Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484.
  • van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017.
  • Brusamolino E, Baio A, Orlandi E, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487–6493.
  • Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–214.
  • Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–1886.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.